Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial

(2015) Shizuka Kaneko et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

(2014) Gregory R. Fulcher et al.   DIABETES CARE

Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial

(2014) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation

(2014) N Waugh et al.   HEALTH TECHNOLOGY ASSESSMENT

National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011

(2014) Kasia J. Lipska et al.   JAMA Internal Medicine

National Estimates of Insulin-Related Hypoglycemia and Errors Leading to Emergency Department Visits and Hospitalizations

(2014) Andrew I. Geller et al.   JAMA Internal Medicine

The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes

(2013) L. Meneghini et al.   DIABETES CARE

Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes

(2013) Stephen C.L. Gough et al.   DIABETES CARE

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

(2013) A. Philis-Tsimikas et al.   DIABETES OBESITY & METABOLISM

Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

(2013) Y. Onishi et al.   DIABETES OBESITY & METABOLISM

Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries

(2013) Marc Evans et al.   Health and Quality of Life Outcomes

Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

(2013) Chantal Mathieu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Quantifying the Direct and Indirect Costs Associated with Severe and Non-Severe Hypoglycaemia in Subjects with Type-2 Diabetes Who Are Treated with Insulin

(2013) V. Foos et al.   VALUE IN HEALTH

Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial

(2013) Yukiko Onishi et al.   Journal of Diabetes Investigation

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective

(2013) Stewart Harris et al.   Patient Preference and Adherence

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial

(2012) I. B. Hirsch et al.   DIABETES CARE

Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)

(2012) B. Zinman et al.   DIABETES CARE

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Alan J Garber et al.   LANCET

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Impaired awareness of hypoglycaemia: a review

(2011) A.J. Graveling et al.   DIABETES & METABOLISM

Insulin analogues and severe hypoglycaemia in type 1 diabetes

(2011) P.L. Kristensen et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Emergency Hospitalizations for Adverse Drug Events in Older Americans

(2011) Daniel S. Budnitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management

(2011) Meryl Brod et al.   VALUE IN HEALTH

Severe Hypoglycaemia Leading to Hospital Admission in Type 2 Diabetic Patients Aged 80 Years or Older

(2010) D. Greco et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Management of severe hypoglycaemia: cultural similarities, differences and resource consumption in three European countries

(2009) M. Lammert et al.   JOURNAL OF MEDICAL ECONOMICS

Costs of managing severe hypoglycaemia in three European countries

(2009) Mette Hammer et al.   JOURNAL OF MEDICAL ECONOMICS

Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France

(2008) P. Vexiau et al.   DIABETES OBESITY & METABOLISM

Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom

(2008) Adrian R Levy et al.   Health and Quality of Life Outcomes

How hypoglycaemia can affect the life of a person with diabetes

(2007) Brian M. Frier   DIABETES-METABOLISM RESEARCH AND REVIEWS